Tag: BRCA mutations

MD Anderson Research Highlights for August 2, 2023

sarah JonasResearch Tip Sheet

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

Recent developments include a novel biomarker that may predict the aggressiveness of pancreatic cancer precursors, insights into the structure and function of a breast and ovarian cancer susceptibility gene, a new approach to overcoming treatment resistance in ovarian cancer, distinguishing features of young-onset rectal cancer, a biomarker and potential target for metastatic lung cancer, machine learning models to better predict outcomes of patients with mantle cell lymphoma (MCL), and a promising therapy for patients with relapsed/refractory MCL.

New findings offer improved therapy of early-stage, BRCA mutation-associated breast cancer

sarah JonasResearch Results

Results were released this week on a new treatment with the potential to improve the outcomes for patients with hereditary BRCA mutations and high-risk, early-stage breast cancer. These results represent the first time a drug that blocks cancer cells from repairing their DNA (called a PARP inhibitor) has been shown to significantly reduce the risk of breast cancer returning in high-risk patients following completion of standard chemotherapy, surgery and radiation therapy.

Study Identifies Never-Before-Seen Dual Function in Enzyme Critical for Cancer Growth

sarah JonasResearch Results

In developing therapies for hard-to-treat breast and ovarian cancers in patients with BRCA gene mutations, scientists aim to identify ways to keep cancer cells from using DNA break repair pathways. New findings demonstrate a previously-unknown capability for polymerase theta (pol theta) – a key enzyme in this repair function – that shows promise as a new avenue for treatment development.

Medical Oncologist Dr. Shilpi Gupta Joins Atlantic Health System Cancer Care’s Comprehensive Breast Health Program

sarah JonasAnnouncement

Atlantic Health System Cancer Care today announced that fellowship-trained medical oncologist, Shilpi Gupta, MD, has joined Morristown Medical Center’s comprehensive breast health program where her focus is breast oncology and research. Dr. Gupta is on staff at Atlantic Hematology Oncology at the hospital’s Carol G. Simon Cancer Center.